|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | New spinal robotic technologies显示文摘Robotic systems in surgery have developed rapidly. Installations of the da Vinci Surgical System® (Intuitive Surgical, Sunnyvale, CA,, USA), widely used in urological and gynecological procedures, have nearly doubled in the United States from 2010 to 2017. Robotics systems in spine surgery have been adopted more slowly;however, users are enthusiastic about their applications in this subspecialty. Spinal surgery often requires fine manipulation of vital structures that must be accessed via limited surgical corridors and can require repetitive tasks over lengthy periods of time — issues for which robotic assistance is well-positioned to complement human ability. To date, the United States Food and Drug Administration (FDA) has approved 7 robotic systems across 4 companies for use in spinal surgery. The available clinical data evaluating their efficacy have generally demonstrated these systems to be accurate and safe. A critical next step in the broader adoption of surgical robotics in spine surgery is the design and implementation of rigorous comparative studies to interrogate the utility of robotic assistance. Here we discuss current applications of robotics in spine surgery, review robotic systems FDA-approved for use in spine surgery, summarize randomized controlled trials involving robotics in spine surgery, and comment on prospects of robotic-assisted spine surgery. | Bowen Jiang Tej DAzad Ethan Cottrill Corinna CZygourakis Alex MZhu Neil Crawford Nicholas Theodore | 2019 | Frontiers of Medicine2019，13，6： | 5 |
| 2 | The effect of age on the job satisfaction of construction workers显示文摘 | Nicholas Chileshe Theodore C. Haupt | 2010 | Journal of Engineering, Design and Technology2010，，1： | 1 |
| 3 | ASurvey of Inter-vehicle Communication Protocols andTheir Applications显示文摘 | THEODORE L PATCHARINEE T NICHOLAS F | 2009 | Communications Surveys&Tuto-rials IEEE2009，11，2： | 1 |
| 4 | A phase Ⅰ/Ⅱa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury显示文摘 | Michael G Fehlings Nicholas Theodore James Harrop | | 0，，05： | 1 |
| 5 | Staircase testing of a titanium alloy in the gagacycle regime 显示文摘 | Ryan Morrissey Theodore Nicholas | 2006 | International Journal of Fatigue2006，28，： | 1 |
| 6 | Notch size effects in HCF behavior of Ti-6Al-4V 1显示文摘 | GEORGE K HARITOS THEODORE NICHOLAS DAVID B LANNING | 1999 | Journal of Fatigue1999，21，： | 1 |
| 7 | Mandibular dental arch changes associated with treatment of crowding using self-ligating and conventional brackets显示文摘 | Nicholas Pandis Argy Polychronopoulou Margarita Makou Theodore Eliades | 2010 | The European Journal of Orthodontics2010，，3： | 1 |
| 8 | Management of Isolated Fractures of the Atlas in Adults显示文摘 | Timothy C. Ryken Bizhan Aarabi Sanjay S. Dhall Daniel E. Gelb R. John Hurlbert Curtis J. Rozzelle Nicholas Theodore Beverly C. Walters Mark N. Hadley | 2013 | Neurosurgery2013，，： | 1 |
| 9 | Atlas Fractures显示文摘 | Udaya K. Kakarla Steve W. Chang Nicholas Theodore Volker K. H. Sonntag | 2010 | Neurosurgery ( Suppl)2010，，3： | 1 |
| 10 | Influence of residual stresses on high cycle fatigue strength of Ti–6Al–4V subjected to foreign object damage显示文摘 | Steven R. Thompson John J. Ruschau Theodore Nicholas | 2001 | International Journal of Fatigue2001，，： | 1 |
| 11 | Oxysterols as promising small molecules for bone tissue engineering: Systematic review显示文摘BACKGROUND Bone tissue engineering is an area of continued interest within orthopaedic surgery,as it promises to create implantable bone substitute materials that obviate the need for autologous bone graft.Recently,oxysterols–oxygenated derivatives of cholesterol-have been proposed as a novel class of osteoinductive small molecules for bone tissue engineering.Here,we present the first systematic review of the in vivo evidence describing the potential therapeutic utility of oxysterols for bone tissue engineering.AIM To systematically review the available literature examining the effect of oxysterols on in vivo bone formation.METHODS We conducted a systematic review of the literature following PRISMA guidelines.Using the PubMed/MEDLINE,Embase,and Web of Science databases,we queried all publications in the English-language literature investigating the effect of oxysterols on in vivo bone formation.Articles were screened for eligibility using PICOS criteria and assessed for potential bias using an expanded version of the SYRCLE Risk of Bias assessment tool.All full-text articles examining the effect of oxysterols on in vivo bone formation were included.Extracted data included:Animal species,surgical/defect model,description of therapeutic and control treatments,and method for assessing bone growth.Primary outcome was fusion rate for spinal fusion models and percent bone regeneration for critical-sized defect models.Data were tabulated and described by both surgical/defect model and oxysterol employed.Additionally,data from all included studies were aggregated to posit the mechanism by which oxysterols may mediate in vivo bone formation.RESULTS Our search identified 267 unique articles,of which 27 underwent full-text review.Thirteen studies(all preclinical)met our inclusion/exclusion criteria.Of the 13 included studies,5 employed spinal fusion models,2 employed critical-sized alveolar defect models,and 6 employed critical-sized calvarial defect models.Based upon SYRCLE criteria,the included studies were found to possess an overall“unclear risk of bias”;54%of studies reported treatment randomization and 38%reported blinding at any level.Overall,seven unique oxysterols were evaluated:20(S)-hydroxycholesterol,22(R)-hydroxycholesterol,22(S)-hydroxycholesterol,Oxy4/Oxy34,Oxy18,Oxy21/Oxy133,and Oxy49.All had statistically significant in vivo osteoinductive properties,with Oxy4/Oxy34,Oxy21/Oxy133,and Oxy49 showing a dose-dependent effect in some cases.In the eight studies that directly compared oxysterols to rhBMP-2-treated animals,similar rates of bone growth occurred in the two groups.Biochemical investigation of these effects suggests that they may be primarily mediated by direct activation of Smoothened in the Hedgehog signaling pathway.CONCLUSION Present preclinical evidence suggests oxysterols significantly augment in vivo bone formation.However,clinical trials are necessary to determine which have the greatest therapeutic potential for orthopaedic surgery patients. | Ethan Cottrill Julianna Lazzari Zach Pennington Jeff Ehresman Andrew Schilling Naomi Dirckx Nicholas Theodore Daniel Sciubba Timothy Witham | 2020 | World Journal of Orthopedics2020，11，7： | 1 |
| 12 | A Survey of Inter-Vehicle Communication ( IVC ) Protocols and Their Applications 显示文摘 | THEODORE L PATCHARINEE Tientrakool Nicholas F | 2009 | IEEE Communications Surveys & Tutorials2009，11，2： | 1 |
| 13 | Body Mass Index and Adverse Perioperative Outcomes Following Hepatic Resection显示文摘 | Amit K. Mathur Amir A. Ghaferi Nicholas H. Osborne Timothy M. Pawlik Darrell A. Campbell Michael J. Englesbe Theodore H. Welling | 2010 | Journal of Gastrointestinal Surgery2010，，8： | 1 |
| 14 | Spondylodiscitis:update on diagnosis and management显示文摘 | Theodore G Sani H Aliyu Nicholas M | 2010 | J Antimicrob Chemother2010，65，3： | 1 |
| 15 | Guidelines for the Management of Acute Cervical Spine and Spinal Cord Injuries: 2013 Update显示文摘 | Beverly C. Walters Mark N. Hadley R. John Hurlbert Bizhan Aarabi Sanjay S. Dhall Daniel E. Gelb Mark R. Harrigan Curtis J. Rozelle Timothy C. Ryken Nicholas Theodore | 2013 | Neurosurgery2013，，： | 1 |
| 16 | Fatigue crack nucleation and growth rate behavior of laser shock peened titanium显示文摘 | John J. Ruschau Reji John Steven R. Thompson Theodore Nicholas | 1999 | International Journal of Fatigue1999，，： | 1 |
| 17 | Int J Fatig显示文摘 | David B Lanning Theodore Nicholas George K Haritos | 2005 | 27:452005，27，： | 1 |
| 18 | Int J Fatig显示文摘 | George K Haritos Theodore Nicholas David B Lanning | 1999 | 21:6431999，21，： | 1 |
| 19 | Int J Fatig显示文摘 | David B Lanning George K Haritos Theodore Nicholas | 1999 | 21(s): 871999，，： | 1 |
| 20 | Investigational growth factors utilized in animal models of spinal fusion: Systematic review显示文摘BACKGROUND Over 400000 Americans annually undergo spinal fusion surgeries, yet up to 40%of these procedures result in pseudoarthrosis even with iliac crest autograft, the current 'gold standard' treatment. Tissue engineering has the potential to solve this problem via the creation of bone grafts involving bone-promoting growth factors(e.g., bone morphogenetic protein 2). A broad assessment of experimental growth factors is important to inform future work and clinical potential in this area. To date, however, no study has systematically reviewed the investigational growth factors utilized in preclinical animal models of spinal fusion.AIM To review all published studies assessing investigational growth factors for spinal fusion in animal models and identify promising agents for translation.METHODS We conducted a systematic review of the literature using PubMed, Embase,Cochrane Library, and Web of Science databases with searches run on May 29 th,2018. The search query was designed to include all non-human, preclinical animal models of spinal fusion reported in the literature without a timespan limit. Extracted data for each model included surgical approach, level of fusion,animal species and breed, animal age and sex, and any other relevant characteristics. The dosages/sizes of all implant materials, spinal fusion rates,and follow-up time points were recorded. The data were analyzed and the results reported in tables and text. PRISMA guidelines were followed for this systematic review.RESULTS Twenty-six articles were included in this study, comprising 14 experimental growth factors: AB204(n = 1); angiopoietin 1(n = 1); calcitonin(n = 3);erythropoietin(n = 1); basic fibroblast growth factor(n = 1); growth differentiation factor 5(n = 4), combined insulin-like growth factor 1 +transforming growth factor beta(n = 4); insulin(n = 1); NELL-1(n = 5); noggin(n= 1); P-15(n = 1); peptide B2 A(n = 2); and secreted phosphoprotein 24(n = 1).The fusion rates of the current gold standard treatment(autologous iliac crest bone graft, ICBG) and the leading clinically used growth factor(BMP-2) ranged widely in the included studies, from 0-100% for ICBG and from 13%-100% for BMP-2. Among the identified growth factors, calcitonin, GDF-5, NELL-1, and P-15 resulted in fusion rates of 100% in some cases. In addition, six growth factors-AB204, angiopoietin 1, GDF-5, insulin, NELL-1, and peptide B2 A-resulted in significantly enhanced fusion rates compared to ICBG, BMP-2, or other internal control in some studies. Large heterogeneity in animal species, fusion method,and experimental groups and time points was observed across the included studies, limiting the direct comparison of the growth factors identified herein.CONCLUSION Several promising investigational growth factors for spinal fusion have been identified herein; directly comparing the fusion efficacy and safety of these agents may inform clinical translation. | Ethan Cottrill A Karim Ahmed Noah Lessing Zachary Pennington Wataru Ishida Alexander Perdomo-Pantoja Sheng-fu Lo Elizabeth Howell Christina Holmes C Rory Goodwin Nicholas Theodore Daniel M Sciubba Timothy F Witham | 2019 | World Journal of Orthopedics2019，10，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员